Office of Health Economics

Amyotrophic lateral sclerosis (ALS) is rare but devastating, with high unmet need, delayed diagnosis & huge socioeconomic burden. Investment in research & new treatments is urgent, and could offer major societal & commercial returns: www.ohe.org/publications...

Patients deserve faster cancer treatment access. APACE framework bridges gaps in Europe’s approval and reimbursement process to drive change. www.ohe.org/publications...

When thinking about relapsed acute leukemia, patients care most about responding to treatment – but quality of life and treatment convenience matter too. Preferences vary, so one size doesn’t fit all.

Healthcare decisions should reflect what patients value most.

www.ohe.org/publications...

Wider access to cell & gene therapies could create more than £20 billion in value over 10 years, benefiting patients, the NHS, and the UK economy. Evidence supports a coordinated system shift. Read the full report www.ohe.org/publications...

Can the NHS be turned around? Prof Anita Charlesworth says yes, but only if prevention and productivity move from vision to action. Read key takeaways from OHE’s 2025 Annual Lecture: www.ohe.org/insights/tur...

Drug shortages are growing, lasting longer, and hitting patients hard. OHE’s submission to Parliament sets out causes, risks, and reforms to strengthen UK supply chains. www.ohe.org/insights/ohe...

Environmental sustainability in the NHS 10 Year Health Plan: The need for green - OHE This is the second in a series of blogs about how the proposals in the recently published 10 Year Plan measure up against some of the most pressing health concerns in the UK.

To close the sustainability gap, creating a health system that is both low-carbon and resilient to climate impacts must be a strategic priority woven into every NHS decision.

Read more about the path to a greener NHS in this Insight by Nadine Henderson: www.ohe.org/insights/env...

Understanding the preferences of people with acute leukemia for different health outcomes - OHE When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe the problems they have with different aspects of their health. In this study, we wan...

Pain/discomfort matters most to people with acute leukemia, but cognition, tiredness, and other aspects shape daily life too. Standard tools can miss these. Capturing patient priorities ensures care and policy improve quality of life, not just clinical outcomes. www.ohe.org/publications...

Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape - OHE The next stop in our around the world in HTAs adventure is Saudi Arabia. This blog breaks down how the Kingdom is reshaping access to new health technologies through regulatory reform, a formal HTA fr...

Saudi Arabia is formalising #HTA, adopting value-based pricing, and restructuring #healthcare delivery. What do these changes mean for #marketaccess and #policy in the region? Read our latest insight: www.ohe.org/insights/sau...

It is Frontotemporal Dementia Awareness Week. OHE is contributing to the PREDICT-FTD consortium, which aims to advance a biomarker-based diagnosis of frontotemporal dementia. www.ohe.org/insights/the-true-cost-and-burden-of-frontotemporal-dementia-early-insights-into-a-pressing-challenge/

The NHS 10 Year Health Plan puts prevention at the centre. Misaligned incentives, behavioural barriers, and risks of widening inequalities raise the question: can prevention truly move from ambition to action? Find out: www.ohe.org/insights/pre...

China’s evolving HTA system is transforming access to medicines for 1.4B people. 700+ drugs added to the NRDL since 2017, but there are still challenges like transparency and data gaps. Read the insight:

Climate action is health action. Health economics can help shape smarter, fairer decisions – from green #HTA to valuing co-benefits of #climatepolicy. www.ohe.org/insights/cli...

What is STRIDES? A new #framework to capture the full value of #AMR diagnostics in tackling #antimicrobial resistance. Read more on how #diagnostics can help fight AMR: www.ohe.org/insights/fro...

How can we use health economics to inform climate-related policy without needing new frameworks?

📆 8 July 2025
🕛 10:00 BST
📍 Virtual event

Register here: www.ohe.org/events/valui...

#healtheconomics #climatechange #sustainability #publichealth

Health reforms in the Middle East are bold, fast, and values-driven. #HTA, workforce, and #pricing models are being reimagined, read our insight on what this means for #healtheconomists: www.ohe.org/insight/heal...

There is a range of ways ex-US payers and pharma companies might respond to President Trump’s “Most Favoured Nation” drug pricing. Will any of them work to lower #US drug prices?

Read more: www.ohe.org/insight/the-trump-administrations-us-drug-pricing-proposal-what-will-happen-next/

New insight: 68% of OECD countries formally use #QALYs in pricing decisions, but practices vary. How consistent is economic evaluation across borders?
www.ohe.org/insight/how-...

#HTA #healtheconomics

New report on STRIDES—a framework to better value AMR #diagnostics. #Diagnostics are key to tackling #AMR, but #policy still overlooks their impact. Read more: www.ohe.org/publications...

Argentina plans a new national #HTA agency, ANEFiTS. A big step for evidence-based #policy, but key questions on governance, transparency & legal power remain. Read more: www.ohe.org/insight/arou...

New insight: a substantial proportion of these medicines do not deliver their intended therapeutic benefits for the individuals taking them, due to genetic variations.
##pharmacogenomics #CERSI

www.ohe.org/insight/pharmacogenomics-testing-a-crucial-piece-to-unlocking-the-full-value-of-medicines/

Vaccines return up to 19x their cost, but adult #immunisation is undervalued. Our new insight calls for long-term investment to boost health, productivity & system resilience. www.ohe.org/insight/prevention-pays-off-so-why-arent-we-doing-more-of-it/

President Trump says the rest of the world “free rides” on the #US – and wants to peg US #drugprices to other countries’. This isn’t a new idea – but what might be different with his latest Executive Order? Read more: www.ohe.org/insight/the-...

New OHE report: Europe is off-track to meet 2030 #HIV eradication targets. Rising diagnoses, late testing & mounting costs demand urgent action. We highlight key barriers, the cost of complacency & solutions. Read more: www.ohe.org/publications...

#publichealth #healtheconomics

How can the #UK prepare for an #ageingsociety? OHE’s submission to a #parliamentary inquiry stressed that keeping as many people as healthy and productive as possible – for as long as possible – is a requisite measure in addressing a shrinking #workforce. Read more: www.ohe.org/insight/offi...

Kenya is making progress on using evidence to guide healthcare decisions. New reforms embed #HTA in #policy, but challenges in capacity, funding and transparency remain. www.ohe.org/insight/arou...

Andy Briggs, presenting at #ISPORMontreal on whether we should be ‘greening’ our HTA methods in a panel organised by @ohenews.bsky.social on Environmental Sustainability and Whole Health. You can read the write up of his presentation on occamresearch.substack.com/p/greening-hta

abstract of a new paper in Value in Health, May 2025, by Mireia Jofre-Bonet and colleagues about the effect of biosimilars on prices in the US

"The Price Effects of Biosimilars In the US" by Mireia Jofre-Bonet et al. concludes the US biosimilars market has become highly competitive; driving price reductions between 2015-2023 with substantial savings for Medicare

➡️ tinyurl.com/PriceEffects...

@ohenews.bsky.social
#HealthEconomics

GLP-1s are changing #obesity care—but access, equity, and patient preferences raise new challenges. Our latest insight looks at what this means for #policy and practice. www.ohe.org/insight/glp-...

#healtheconomics #GLP1

Understanding the Full Value of Long-Acting Therapies: less is more? - OHE Long-acting therapies offer value for chronic disease, improving adherence and outcomes. This OHE report highlights HTA gaps, real-world evidence, and policy needs.

📢 New publication from OHE: Understanding the full value of long-acting therapies: Less is more?

We will also be discussing this research at ISPOR 2025 in Issue Panel 116. Join us for the discussion!

Read it here: www.ohe.org/publications...

#healtheconomics #HTA